Merck, Pfizer well-placed for spinoff benefits

U.S. investors have been pressuring companies to return cash to shareholders via spinoffs, and Goldman Sachs points to Merck ($MRK) and Pfizer ($PFE) as two firms that could benefit most from asset sales. Pfizer is exploring options for its animal health and nutritionals businesses. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…